BOSTON - Researchers from Massachusetts Eye and Ear/Harvard Medical School have conducted a clinical trial comparing the safety and efficacy of topical tacrolimus, an immunosuppressive therapy, and topical methylprednisolone, a steroid medication, in patients with ocular graft-versus-host-disease (GVHD) -- a complication associated with allogeneic bone marrow transplants in which the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface.
Culture
A new large-scale population-based study from The University of Texas Medical Branch at Galveston showed for the first time that older men using testosterone therapy were less likely to have complications that require them to go back to the hospital within a month of being discharged than men not using this therapy. The study is currently available in Mayo Clinic Proceedings.
MAYWOOD, IL - A new generation of blood thinners can reduce the risk of stroke in patients with atrial fibrillation, without requiring frequent monitoring and dietary restrictions.
But special attention must be given to the patient's age, kidney function and other factors before prescribing the new medications, according to an article by neurologists at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.
The report by Rochelle Sweis, DO and José Biller, MD, is published in the journal Current Treatment Options in Cardiovascular Medicine.
A new study led by researchers with the Johns Hopkins Center for Gun Policy and Research, part of the Johns Hopkins Bloomberg School of Public Health, finds that state-level policy changes can impact the number of fatal and non-fatal assaults, including shootings, of law enforcement officers. The report is published in Injury Prevention.
A multi-institutional study led by a Massachusetts General Hospital (MGH) investigator finds significant racial disparities in the risk that patients being treated for gout will develop a serious, sometimes life-threatening adverse reaction to the most commonly prescribed medication. The increased risk closely correlates with the frequency of a gene variant previously associated with that adverse reaction, supporting recommendations to screen for that variant in patients from those populations.
AURORA, Colo. (April 13, 2016) - Expanding insurance coverage for a type of in vitro fertilization known as elective single-embryo transfer could lead to improved health outcomes and lower health care costs, according to a newly published study that included researchers from the University of Colorado School of Medicine.
The study, published in the journal Fertility and Sterility, offers a national survey of outcomes for 263,375 in vitro fertilization (IVF) cycles in the United States and finds that elective single-embryo transfer leads to fewer adverse outcomes.
Until now, no large-scale scientific studies had been done into the impact of the economic crisis on homeless people. A study by the University of the Basque Country has explained how, between 2008 and 2012, the employment situation, together with cuts to certain state benefits, has put the brakes on the reintegration of homeless people into society, especially if they are foreign.
Boston -- Blood-contacting implantable medical devices, such as stents, heart valves, ventricular assist devices, and extracorporeal support systems, as well as vascular grafts and access catheters, are used worldwide to improve patients' lives. However, these devices are prone to failure due to the body's responses at the blood-material interface; clots can form and inflammatory reactions can prevent the device from performing as indicated. Currently, when this occurs, the only solution is to replace the device.
April 13, 2016, Barcelona, Spain: A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress™ 2016 in Barcelona, Spain.
April 13, 2016, Barcelona, Spain: Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.
The large retrospective cohort study, presented today at The International Liver CongressTM in Barcelona, Spain found 29% of patients who had a history of HCC re-developed the condition during or after taking DAAs.
April 13, 2016, Barcelona, Spain: Two separate studies presented today at The International Liver Congress™ 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).
April 13, 2016, Barcelona, Spain: The growing burden of alcohol-related liver disease (ARLD) could be reduced if hospitals introduced a simple universal screening procedure for those attending acute and emergency hospital settings, according to a new study shared today at The International Liver Congress™ in Barcelona, Spain.
The first network to look at the interconnected nature of people and places in large cities is not only able to quantify the social diversity of a particular place, but can also be used to predict when a neighbourhood will go through the process of gentrification, which is associated with the displacement of residents of a deprived area by an influx of a more affluent population.
The researchers behind the study, led by the University of Cambridge, will present their results today (13 April) at the 25th International World Wide Web Conference in Montréal.
"Eureka," the state motto for California, comes from the Greek word for "I have found it." There seems to be something in the mythology of California attuned to seeking and finding--a fitting spirit for the site of the upcoming American Geriatrics Society (AGS) Annual Scientific Meeting (AGS16), held this year in Long Beach, Calif., May 19-21.
LA JOLLA--Salk scientists have solved a longstanding problem in the effort to create replacement cells for diabetic patients. The team uncovered a hidden energy switch that, when flipped, powers up pancreatic cells to respond to glucose, a step that eluded previous research. The result is the production of hundreds of millions of lab-produced human beta cells--able to relieve diabetes in mice.